BACKGROUND: Acute exacerbation of chronic obstructive pulmonary disease is associated with increased airway and systemic inflammation. However, the correlation between acute exacerbation/convalescence of chronic obstructive pulmonary disease (COPD) and simultaneous changes of high mobility group protein B1 (HMGB1) and soluble RAGE (sRAGE) levels has not been clearly clarified. The aim of this study was to assess these issues. METHODS: A total of 44 COPD patients were recruited. Following a structured interview, plasma levels of HMGB1, sRAGE, fibrinogen and serum level of high-sensitivity C-reactive protein (hsCRP) were measured in patients with acute exacerbation of COPD (AECOPD) within 24 h of hospitalization and pre-discharge (convalescence). All patients were examined with spirometry in convalescence of COPD. RESULTS: There was a significant decline in plasma HMGB1 (P<0.01), sRAGE (P<0.05), fibrinogen (P<0.01) and serum hsCRP (P<0.01) levels from acute exacerbation to convalescence phase of COPD. Changes of sRAGE was significantly correlated with changes of HMGB1 (r=0.4, P=0.007). COPD disease status correlated with the ratio of HMGB1/sRAGE, but not gender, age, course of disease, smoking history and FEV1% pred. Levels of HMGB1 and sRAGE were the highest in the current smoker group, and significantly decreased in ex-smoker group in both acute exacerbation and convalescence phase of COPD, however, their levels in never smoker group were higher than ex-smoker group in either phase of COPD. CONCLUSIONS: HMGB1 and sRAGE levels were dynamically changed between exacerbation and convalescence phase of COPD, HMGB1 and sRAGE were likely not only a potential marker in COPD exacerbation but also a therapeutic target for COPD treatment.
BACKGROUND: Acute exacerbation of chronic obstructive pulmonary disease is associated with increased airway and systemic inflammation. However, the correlation between acute exacerbation/convalescence of chronic obstructive pulmonary disease (COPD) and simultaneous changes of high mobility group protein B1 (HMGB1) and soluble RAGE (sRAGE) levels has not been clearly clarified. The aim of this study was to assess these issues. METHODS: A total of 44 COPDpatients were recruited. Following a structured interview, plasma levels of HMGB1, sRAGE, fibrinogen and serum level of high-sensitivity C-reactive protein (hsCRP) were measured in patients with acute exacerbation of COPD (AECOPD) within 24 h of hospitalization and pre-discharge (convalescence). All patients were examined with spirometry in convalescence of COPD. RESULTS: There was a significant decline in plasma HMGB1 (P<0.01), sRAGE (P<0.05), fibrinogen (P<0.01) and serum hsCRP (P<0.01) levels from acute exacerbation to convalescence phase of COPD. Changes of sRAGE was significantly correlated with changes of HMGB1 (r=0.4, P=0.007). COPD disease status correlated with the ratio of HMGB1/sRAGE, but not gender, age, course of disease, smoking history and FEV1% pred. Levels of HMGB1 and sRAGE were the highest in the current smoker group, and significantly decreased in ex-smoker group in both acute exacerbation and convalescence phase of COPD, however, their levels in never smoker group were higher than ex-smoker group in either phase of COPD. CONCLUSIONS:HMGB1 and sRAGE levels were dynamically changed between exacerbation and convalescence phase of COPD, HMGB1 and sRAGE were likely not only a potential marker in COPD exacerbation but also a therapeutic target for COPD treatment.
Entities:
Keywords:
Chronic obstructive pulmonary disease (COPD); biomarker; convalescence; exacerbation; high mobility group protein B1 (HMGB1); soluble RAGE (sRAGE)
Authors: Mohamed Lamkanfi; Anasuya Sarkar; Lieselotte Vande Walle; Alberto C Vitari; Amal O Amer; Mark D Wewers; Kevin J Tracey; Thirumala-Devi Kanneganti; Vishva M Dixit Journal: J Immunol Date: 2010-08-27 Impact factor: 5.422
Authors: A Di Stefano; G Caramori; T Oates; A Capelli; M Lusuardi; I Gnemmi; F Ioli; K F Chung; C F Donner; P J Barnes; I M Adcock Journal: Eur Respir J Date: 2002-09 Impact factor: 16.671
Authors: Barry I Hudson; Angela M Carter; Evis Harja; Anastasia Z Kalea; Maria Arriero; Hojin Yang; Peter J Grant; Ann Marie Schmidt Journal: FASEB J Date: 2007-12-18 Impact factor: 5.191
Authors: Esmaeil Mortaz; Ian M Adcock; Fabio L M Ricciardolo; Mohammad Varahram; Hamidreza Jamaati; Ali Akbar Velayati; Gert Folkerts; Johan Garssen Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240
Authors: Jarrett D Morrow; Xiaobo Zhou; Taotao Lao; Zhiqiang Jiang; Dawn L DeMeo; Michael H Cho; Weiliang Qiu; Suzanne Cloonan; Victor Pinto-Plata; Bartholome Celli; Nathaniel Marchetti; Gerard J Criner; Raphael Bueno; George R Washko; Kimberly Glass; John Quackenbush; Augustine M K Choi; Edwin K Silverman; Craig P Hersh Journal: Sci Rep Date: 2017-03-13 Impact factor: 4.379